Austraalia - inglise - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - cyproterone acetate -

Austraalia - inglise - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - cyproterone acetate -

Austraalia - inglise - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - eplerenone -

Austraalia - inglise - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - medroxyprogesterone acetate -

Austraalia - inglise - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - piperazine oestrone sulfate -

Austraalia - inglise - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - medroxyprogesterone acetate -

Austraalia - inglise - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - medroxyprogesterone acetate -

Austraalia - inglise - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - testosterone -

Austraalia - inglise - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - cyproterone acetate, quantity: 50 mg - tablet, uncoated - excipient ingredients: magnesium stearate; lactose monohydrate; maize starch; colloidal anhydrous silica; povidone - women: moderately severe to severe signs of androgenization. moderately severe/severe forms of hirsutism.moderately severe/severe androgen-dependent loss of scalp hair (moderately severe/severe androgenic alopecia). moderately severe/severe forms of acne and/or seborrhoea associated with other features of androgenization.cyproterone acetate inhibits the influence of male sex hormones which are also produced by the female. it is thus possible to treat diseases in women caused either by increased production of androgens or a particular sensitivity to these hormones. hirsutism and alopecia may be expected to recur over a period of time after cessation of treatment.if androcur is taken during pregnancy, the properties of the preparation may lead to signs of feminisation in the male foetus. therefore, in women of childbearing potential, pregnancy must be excluded at the commencement of treatment and ethinyloestradiol taken as well to ensure contraception. this also promotes regular menstruation.men:reduction of drive in sexual deviations androcur reduces the force of the sexual urge in men with sexual deviations. whilst under treatment the man can control himself better in a predisposing stimulatory situation, but there is no influence on any deviating direction of sexual drive. abnormal patterns of sexual behaviour require treatment when they are distressing to the patient. a pre-requisite for therapy is the desire by the patient for treatment.androcur therapy should be supplemented by psychotherapeutic and sociotherapeutic measures in order to exploit the period of reduced drive for personal and social re-orientation.inoperable prostatic carcinoma to suppress "flare" with initial lhrh analogue therapy in long term palliative treatment where lhrh analogues or surgery are ineffective, not tolerated, contraindicated or where oral therapy is preferred in the treatment of hot flushes in patients treated with lhrh analogues or who have had orchidectomy.

Uus-Meremaa - inglise - Medsafe (Medicines Safety Authority)

viatris limited - eplerenone 25mg - film coated tablet - 25 mg - active: eplerenone 25mg excipient: croscarmellose sodium hypromellose lactose monohydrate magnesium stearate microcrystalline cellulose opadry yellow ys-1-12524-a purified talc purified water   sodium laurilsulfate - inspra is indicated to reduce the risk of cardiovascular death in combination with standard therapy in patients who have evidence of heart failure and left ventricular impairment within 3 to 14 days of an acute myocardial infarction.